ClinicalTrials.gg
Not yet recruitingNCT07107178Updated Aug 6, 2025

A Clinical Study of BT02 for the Treatment of Patients With Advanced Malignant Melanoma

A Phase 1 interventional study of BT02 in Advanced Melanoma and Advanced Solid Tumor, sponsored by Biotroy Therapeutics. Not yet recruiting. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-08-06.

Sponsored by Biotroy Therapeutics · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
58
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Study summary

The goal of this clinical trial is to learn about the safety, tolerability and preliminary effectiveness of a treatment for patients with advanced melanoma,regardless of gender, aged between 18 and 75 years (inclusive).

Participants will receive the investigational product intravenously every two or three weeks. The treatment will continue for a maximum of two years for those who do not show signs of disease progression or experience intolerable side effects.

02

Conditions studied

  • Advanced Melanoma
  • Advanced Solid Tumor

Browse trials for

03

In context

Melanoma

3,373 studies on the registry are indexed under Melanoma; 580 are open to participants now.

This study's planned enrollment of 58 is above the median of 40 across 2,650 interventional studies indexed under Melanoma.

Browse Melanoma studies →

Lead sponsor

Biotroy Therapeutics is the lead sponsor of 3 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients with or cytologically confirmed diagnosis of unresectable locally advanced or malignant melanoma (except for uveal melanoma) who have failed in the prior systemic therapy .
  2. Adequate organ and hematologic function.
  3. At least 1 extracranial .
  4. An activity status score of 0-1.
  5. A of ≥ 3 months.
  6. Eligible participants of (both males and females) must agree to using effective throughout the study period.
  7. Good compliance and willingness to follow up.

Exclusion criteria

Exclusion Criteria:

  1. Prior to first dose, received systemic antitumor therapy , scheduled major surgical procedure within 4 weeks , received systemic immunostimulants within 5 half-lives and systemic or other medications within 14 days.
  2. A history of active disease within the past 2 years.
  3. A history of cardiovascular disease, severe cardiac rhythm/conduction abnormalities or \<50%. A history of severe pulmonary disease that may lead to severe episodes of dyspnea.
  4. A severe acute or chronic infection when enrollment.
  5. Remaining the toxic reaction in previous anti-tumor therapy that has not recovered to ≤ Grade 1 .
  6. Unresolved > grade 1 irAE or the history of a grade ≥ 3 irAE in previous immunotherapy, or known to the formulation of the product.
  7. Clinically active or meningeal .
  8. A history of other type of .
  9. Received a within 28 days prior to the administration of the investigational product.
  10. Poor compliance.
  11. A history of alcohol/drugs abuse.
  12. Current pregnancy or breastfeeding.
  13. Other severe physical or mental illnesses or abnormal laboratory test results that the investigator deems unsuitable for participation in this study considering safety and compliance.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
58 participants (estimated)

Study arms

  • Experimental
    dose escalation and expansion

    Drug: BT02

Interventions

  • DrugBT02

    monoclonal antibody injection with intravenous administration every 2 or 3 weeks

06

What researchers measure

Primary outcomes

  1. Adverse events

    Time frame: Through the study completion, an average of 2 years

  2. Dose limited toxicity(DLT)

    Time frame: Through the dose escalation phase, an average of 8 months

  3. Maximum tolerable dose(MTD)

    Time frame: Through the dose escalation phase, an average of 8 months

  4. Recommended phase 2 dose(RP2D)

    Time frame: Through the study completion, an average of 2 years

Secondary outcomes

  1. Objective response rate (ORR) on tumor assessments

    Time frame: Through the study completion, an average of 2 years

  2. Progression-free survival (PFS) on tumor assessments

    Time frame: Through the study completion, an average of 2 years

  3. Overall survival (OS)

    Time frame: Through the study completion, an average of 2 years

  4. Duration of response (DoR) on tumor assessments

    Time frame: Through the study completion, an average of 2 years

  5. Disease control rate (DCR) on tumor assessments

    Time frame: Through the study completion, an average of 2 years

  6. Mean and median Area under the curve (AUC) of BT02 following first dose and repeated administration at each dose level

    Time frame: Through the study completion, an average of 2 years

  7. Mean and median Maximum concentration (Cmax) of BT02 following first dose and repeated administration at each dose level

    Time frame: Through the study completion, an average of 2 years

  8. ADA and NAb incidence

    Time frame: Through the study completion, an average of 2 years

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Aug 2025; primary completion for May 2027, 21 months later.

Of 225 industry-sponsored phase 1 interventional studies under Melanoma, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 66. This study's planned 21 months is below that.

Counting every sponsor, half of 411 studies reached it within 49 months; a quarter within 31 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 16, 2025
First posted
Aug 6, 2025
StartEst.
Aug 8, 2025
Primary completionEst.
May 2027
CompletionEst.
Aug 2027
Last update
Aug 6, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 6, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07107178
Lead sponsor
Biotroy Therapeutics
Collaborators
Peking University Cancer Hospital and Institute
Responsible party
Sponsor
First posted
Aug 6, 2025
Start date
Aug 8, 2025 (estimated)
Primary completion
May 2027 (estimated)
Completion
Aug 2027 (estimated)
Last update
Aug 6, 2025

Study contacts

Clinical development director
Contact
clin.oper@biotroy.cn
+86-18602185973
Jun Guo, MD
principal investigator · Peking University Cancer Hospital & Institute

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: BT02

Start the discussion